lapatinib has been researched along with Oncogene Addiction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Angelis, C; Osborne, CK; Pascual, T; Prat, A; Reis-Filho, JS; Rimawi, MF; Schiff, R; Veeraraghavan, J | 1 |
| Canese, R; Casalini, P; Castagnoli, L; Di Nicola, M; Dugo, M; Faraci, S; Iorio, E; Koschorke, A; Morelli, D; Nanni, P; Pupa, SM; Tagliabue, E; Vernieri, C | 1 |
1 review(s) available for lapatinib and Oncogene Addiction
| Article | Year |
|---|---|
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Oncogene Addiction; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trastuzumab; Tumor Microenvironment | 2017 |
1 other study(ies) available for lapatinib and Oncogene Addiction
| Article | Year |
|---|---|
Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Italy; Lactic Acid; Lapatinib; Magnetic Resonance Spectroscopy; Mice; Oncogene Addiction; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Up-Regulation | 2019 |